Podcast appearances and mentions of david holtzman

David Holtzman and David Carvalho from Naoris Protocol delve into the recent bankruptcy of 23andMe, a leading genetic testing company. They explore the implications for data security and privacy, discussing how the sale of 23andMe's vast genetic database raises concerns about the protection of personal information. 

Send us a textCybersecurity enthusiasts and curious minds alike are in for a treat with our conversation featuring the esteemed David Holtzman, a cybersecurity virtuoso whose journey will both inspire and educate. Discover why the real mastery in cybersecurity transcends formal certifications, as David shares his formative experiences from high school to the present. His story emphasizes the critical role of curiosity and problem-solving skills, offering valuable insights for those venturing into this ever-evolving field. You'll gain a fresh perspective on what it truly takes to be an expert in cybersecurity as David and I explore the foundational knowledge and mindset essential for success.Shift gears with us as we explore a captivating transition from the allure of traditional luxury sports cars to the groundbreaking innovation of Tesla vehicles. Our discourse navigates the shift in skills from mechanical to digital and unravels the challenges of maintaining vintage cars versus embracing new-age technology. Dive into the quirks of modern tech frustrations, such as dealing with printers, against a backdrop of fascinating anecdotes from my NSA experience. This segment paints a vivid picture of how technology has transformed both personal passions and professional landscapes over the decades.Rounding out our conversation, we tackle the future of AI-driven cybersecurity and the pressing concerns around AI security and privacy. As we weave through the complex tapestry of intelligence work from the past to the potential of decentralized systems, we consider the implications of centralization and the innovations of web3. Witness the exciting possibilities of blockchain in enhancing network security, and reflect on the importance of interdisciplinary skills that prepare professionals for the unknowns of the tech world. This episode promises to enlighten, challenge, and inspire those seeking to understand the nuanced world of cybersecurity and technology's future.Support the showFollow the Podcast on Social Media!Instagram: https://www.instagram.com/secunfpodcast/Twitter: https://twitter.com/SecUnfPodcastPatreon: https://www.patreon.com/SecurityUnfilteredPodcastYouTube: https://www.youtube.com/@securityunfilteredpodcastTikTok: Not today China! Not today

Today on the Social-Engineer Podcast: The Security Awareness Series, Chris is joined by David Holtzman. David has been the CTO for Network Solutions, Chief Scientist at IBM, CTO & Cybersecurity advisor to 2 presidential candidates, and a former intelligence agent. David is now advising on web3 and blockchain. [Jan 20, 2025]   00:00 - Intro 00:18 - Intro Links: -          Social-Engineer.com - http://www.social-engineer.com/ -          Managed Voice Phishing - https://www.social-engineer.com/services/vishing-service/ -          Managed Email Phishing - https://www.social-engineer.com/services/se-phishing-service/ -          Adversarial Simulations - https://www.social-engineer.com/services/social-engineering-penetration-test/ -          Social-Engineer channel on SLACK - https://social-engineering-hq.slack.com/ssb -          CLUTCH - http://www.pro-rock.com/ -          innocentlivesfoundation.org - http://www.innocentlivesfoundation.org/                                                02:01 - David Holtzman Intro 02:30 - The Ever-Changing Threat Landscape 05:35 - Insecure Software 08:57 - Not All CISO's are Equal 12:05 - Making a Good CISO 15:33 - It's About People 17:34 - Lack of Accountability 21:28 - Rise of the AI 26:31 - The Approach of Web3 29:23 - The Blockchain Fix (For Now) 32:39 - Stuck in the Cloud 36:34 - Find David Holtzman online -          Website: davidholtzman.com 36:55 - Book Recommendations -          Crossing the Chasm - Geoffrey Moore -          How to Survive Identity Theft – David Holtzman -          Privacy Lost - David Holtzman 38:46 - Mentors -          Steve Jobs -          John Perry Barlow 42:16 - Wrap Up & Outro -          www.social-engineer.com -          www.innocentlivesfoundation.org

Imagine a mesh network of AI-powered nodes that could validate the security of your organization's systems and applications. It's a clever use of blockchain to add security to real-world devices, and, best of all, it will feature post-quantum cryptography. How soon will this technology simplify security for businesses and governments worldwide? And might this kind of approach even prevent killer robots? Join host Konstantinos Karagiannis for a chat with David Carvalho and David Holtzman from Naoris Protocol.  For more on Naoris Protocol, visit www.naorisprotocol.com/.  Visit Protiviti at www.protiviti.com/US-en/technology-consulting/quantum-computing-services to learn more about how Protiviti is helping organizations get post-quantum ready.  Follow host Konstantinos Karagiannis on all socials: @KonstantHacker and follow Protiviti Technology on LinkedIn and Twitter: @ProtivitiTech.  Questions and comments are welcome!   Theme song by David Schwartz, copyright 2021.   The views expressed by the participants of this program are their own and do not represent the views of, nor are they endorsed by, Protiviti Inc., The Post-Quantum World, or their respective officers, directors, employees, agents, representatives, shareholders, or subsidiaries.  None of the content should be considered investment advice, as an offer or solicitation of an offer to buy or sell, or as an endorsement of any company, security, fund, or other securities or non-securities offering. Thanks for listening to this podcast. Protiviti Inc. is an equal opportunity employer, including minorities, females, people with disabilities, and veterans.

In this episode of Global Risk Community's Risk Management Show, we dive into the world of cybersecurity with David Holtzman, Chief Strategy Officer at Naoris Protocol and former Chief Scientist at IBM. We discussed his bold strategy to fight cyber threats by leveraging aggressive cybersecurity responses. With an illustrious career spanning roles such as designer of the global DNS system for ICANN and White House cybersecurity adviser, David brings invaluable insights into the risks and challenges of both centralized and decentralized systems. He highlights the importance of decentralized technologies and the role they play in enhancing security resilience against growing cyber threats. If you want to be our guest or suggest someone, send your email to info@globalriskconsult.com with the subject line "Guest Suggestion." Join us in exploring cutting-edge solutions and stay ahead in the ever-evolving landscape of cyber security.

In today's episode, we review the neuroscience behind Alzheimer's Disease. Using material presented in Brain Facts published by the Society for Neuroscience, we talk about the prevalence and impact of the disease, the symptoms, how it is typically diagnosed, proposed causes and pathology, the genetics of the disease, and current treatments. Our guest is Dr. David Holtzman, MD, the Barbara Burton and Reuben M. Morriss III Distinguished Professor of Neurology, the Scientific Director for the Hope Center for Neurological Disorders, and Associate Director of the Knight Alzheimer's Disease Research Center at the Washington University School of Medicine. His lab is mainly focused on trying to understand the basic mechanism that underlies neurodegeneration, particularly as they are relevant to Alzheimer's Disease. In addition to being a renowned neurologist and neuroscientist, Dr. Holtzman is the co-founder of C2N Diagnostics, former chair of the Washington University Department of Neurology, and has served as the president of the American Neurological Association. Timestamps:(00:00:00 - 00:01:02) - Intro(00:01:02 - 00:21:00) - Alzheimer's Disease (Ankit Only)(00:21:00 - 01:11:33) - Conversation with Dr. Holtzman(01:11:33 - 01:12:55) - OutroWebsite:Email: brainbeepodcast@gmail.comTwitter: @brainbeepodcastHosted by @iAnkitChoudhury. Advised by Dr. Erik Herzog. Music by Coma-Media from Pixabay.

The possible relationship between metabolic disorders, elevated lactic acid levels, and features of autism spectrum disorder have been described in the medical literature since the early 90’s. In fact, much research exploring the correlation between autism or ASD (autism spectrum disorder) and mitochondrial dysfunction has been published throughout the last decade, long before the Hannah Poling case (March 2008) brought the association to the public’s attention. Since the US Vaccine Compensation Board determined, based on Hannah Poling’s case, that “vaccines significantly aggravated an underlying mitochondrial disorder causing brain damage with features of autism spectrum disorder”, a whirlwind of confusion amongst parents of affected children has occurred. Are vaccines safe? Do children with mitochondrial disease have a potential to develop autism, or do children with autism have an underlying mitochondrial disorder? Is mitochondrial dysfunction the “cause” of autism or behavior compatible with ASD? What do we really know and understand about the relationship between autism spectrum disorders and mitochondrial cytopathies? Join us as Dr. David Holtzman from Massachusetts General Hospital shares his perspective and research on the autism-mitochondrial disease debate.

Bill Curtis and Jane Albrecht continue their discussion on cybersecurity with author and tech-wiz, David Holtzman. What’s a Zombie Bot? Has a Trojan attacked your computer? How can we protect ourselves from Hackers? This episode will both scare and enlighten you to all matters of personal and business cybersecurity. David Holtzman is a world-class information technologist, currently working with global block chain companies, with deep expertise in privacy, encryption, ethics, cybersecurity, digital registries and intellectual property. Episode Timestamps: 00:52 Hacking, Phishing, and Personal Attacks 1:52 How Hackers Attack YOU 4:07 Antivirus Software 5:34 No Real Protection Against Hacking 6:55 Real Life Hacking Examples 7:43 Things you can check before being Hacked 10:37 Hacking Cases during Covid 11:48 What not to do to stay safe from Hackers and VPN 13:07 Passwords 15:07 Password Lockers and Hacks 15:52 Positive Takeaways and Hacking 19:42 Insider Threats and Business 21:48 Individual Responsibility and Old-World Business Tactics 24:06 Final Words  ---------------------- Learn More:  https://www.curtco.com/meetmeinthemiddle Follow Us on Twitter: https://www.twitter.com/politicsMMITM Hosted by: Bill Curtis and Jane Albrecht Edited and Sound Engineering by: Joey Salvia Theme Music by: Celleste and Eric Dick A CurtCo Media Production https://www.curtco.com See omnystudio.com/listener for privacy information.

Bill Curtis and Jane Albrecht discuss cybersecurity with author and tech-wiz, David Holtzman. They dive deep into the Colonial Pipeline Hack, ransomware, and Solar Winds. You’ll learn about the capabilities of Russia, China, and other nations in the cyber-wars. Do you want to know what Zero Day means, who’s DarkSide, Fancy Bear and Cozy Bear?... which software is the safest, Apple or Microsoft? And how wars will be fought in the future? This two-part series on cyber-intelligence will certainly deliver. Episode Timestamps: 3:16 Why do countries get hacked? David Holtzman is a world-class information technologist, currently working with global block chain companies, with deep expertise in privacy, encryption, ethics, cybersecurity, digital registries and intellectual property. 5:05 The Colonial Pipeline Hack 6:16 Panic Buying and Hacks (DarkSide) 9:19 Two Types of Hackers 10:30 Negotiating with Hackers 11:08 The Solar Winds Hack and Russia 12:54 Deduction and knowing who’s the Hacker 14:34 Tracking what information was hacked 16:16 How to handle the backdoor second hack attack 17:45 Lessons Learned from Hackers and USA Cyber intelligence 20:36 Trump and classified intelligence 21:36 Do we have proof that Trump passed info onto the Russians? 23:36 What is Zero Day? 24:54 Apple vs Microsoft and Hacking 28:02 Mutual assured annihilation 29:50 Ramifications of Hacking 32:44 Cold War References and destruction 34:00 Defending against Russian Aggression  ---------------------- Learn More:  https://www.curtco.com/meetmeinthemiddle Follow Us on Twitter: https://www.twitter.com/politicsMMITM Hosted by: Bill Curtis and Jane Albrecht Edited and Sound Engineering by: Joey Salvia Theme Music by: Celleste and Eric Dick A CurtCo Media Production https://www.curtco.com See omnystudio.com/listener for privacy information.

Dr. David Holtzman is the Andrew B. and Gretchen P. Jones Professor and Chairman of Neurology, Professor of Developmental Biology, Associate Director of the Alzheimer’s Disease Research Center, and a Head of the Hope Center for Neurological Disorders at Washington University in St. Louis. Much of the research in David’s lab is dedicated to better understanding the mechanisms underlying neurodegeneration, particularly looking at mechanisms and biomarkers of Alzheimer’s disease. In his free time, David loves playing tennis, road bicycling, hiking, going to vineyards, and traveling. He particularly enjoys exploring the culture of different places while traveling with his wife. David received his Medical Degree from Northwestern University and completed Residency in Neurology at the University of California, San Francisco. David has received many awards and honors during his career, including a Paul Beeson Physician Faculty Scholar Award in Aging Research, the Potamkin Prize from the American Academy of Neurology for research on Alzheimer’s disease, a MERIT award from the National Institute on Aging, the MetLife Award for research on Alzheimer’s disease, and two of his research discoveries were listed in the top 50 scientific innovations in 2006 by Scientific American. He is also an elected member of the American Neurological Association, the American Society for Clinical Investigation, and the Institute of Medicine of the National Academy of Sciences. In our interview, David tells us more about his life and research.

Alzheimer's disease is a devasting illness with no effective treatment. But research is progressing rapidly and current clinical trials offer hope for a future disease-modifying therapy. In this week’s episode, I interview Dr. David Holtzman on the current state of Alzheimer’s research. We discuss his professional development as a physician scientist, his founding of the company C2N diagnostics, and his opinions on the current state and future of Alzheimer’s research. Dr. Holzman got his MD from Northwestern University and then completed a neurology residency and post-doctoral research at UCSF. He is the chairman of the neurology department at Washington University and is the scientific director of the Hope Center for Neurological Disorders. He is the Associate Director of the Knight ADRC and the president of the American Neurological Association. Time stamps: 02:18: Introduction and professional background 14:53: Starting an independent research lab 18:08: Becoming chairman of neurology at Washington University 24:24: Founding C2N diagnostics 29:30: Alzheimer’s background and patient case 32:15: Patient education on Alzheimer’s disease (AD) 36:30: Mechanisms of disease activity in AD 47:12: Future disease modifying treatments for AD 55:20: Future biomarkers for AD 57:40: Emerging research areas for AD Disclosures: Dr. Holtzman is the scientific co-founding member of C2N diagnostics. He has performed consulting work for Eli Lilly and Denali therapeutics. Brain Boy Neurology reports no relevant financial disclosures.

Today, in recognition of Alzheimer’s and Brain Awareness month, we'll hear from Dr. David Holtzman, professor and chair of neurology at Washington University in St Louis. Dr. Holtzman's work has helped to clarify the relationship between Apolipoprotein E4, or apoE4, and Alzheimer's disease. He is also working to develop CSF biomarkers for Alzheimer's, and he has worked on the development of anti-amyloid beta and anti-tau antibodies for now being evaluated through clinical trials in patients with the disease. ANA’s education manager, Jen Hurley, spoke with Dr. Holtzman about the current state of research in biomarkers for Alzheimer’s disease. Dr. Holtzman wishes to disclose that he is a co-founder with equity in the company C2N Diagnostics, a biotech start up focusing on blood biomarkers for AD; he is on the Scientific advisory board of C2N Diagnostics and Denali Therapeutics, and consults for Genentech and Idorsia. Series 1, Episode 13

In this episode of The Risk Perspective, we are joined by David Holtzman, Executive Advisor at CynergisTek, and industry-recognized HIPAA expert. We are also excited to be joined by a new guest, Andrew Mahler, Senior Manager of Privacy and Compliance Services at CynergisTek. Andrew has a background serving as an Investigator for the U.S Department of Health and Human Services Office for Civil Rights (OCR).Together, Andrew and David highlight and discuss major HIPAA violations in the past, speak about the importance of OCR regulations and involvement, as well as talk about how HIPAA disclosures to the media have changed during the time of COVID-19. This 34-minute episode deep dives into HIPAA media disclosures and is sure to benefit all listeners from marketing specialists to CISO.Links To Content and Articles:Read David Holtzman's blog 'OCR Warns Hospitals: No News Media in Treatment Areas Without Patient Authorization' written on MAY 27, 2020. David Holtzman was recently quoted in HealthcareInfoSecurity's article 'Inside Job at Clinics: Mobile Phone Used for Fraud', written by Marianne Kolbasuk McGee to discuss potential risks posed by employees inappropriately using personal devices during COVID-19.For a full repository of COVID-19 crisis resources, visit our CTEK COVID-19 Communications page for news, articles, podcasts, and more.Contact us with any questions regarding the regulatory changes during the COVID-19 crisis.

David Holtzman, Executive Advisor for CynergisTek sits down to discuss how healthcare organizations can flatten the curve in the spike of cybersecurity incidents that we are seeing during the COVID-19 pandemic. He will discuss strategies to leverage training materials designed to increase the information security IQ for health care providers and administrative staff working from home or using their personal devices to access information networks. David will also explore why video conferencing and text messaging technologies that meet the requirements of the HIPAA Security Rule standards could provide healthcare organizations resilience in this exceptional time. Read David Holtzma's article "COVID-19: Tips for Secure Remote Worksites, Telehealth Video, and Messaging" on more information about telehealth and remote worksites. 

David Holtzman, Executive Advisor for CynergisTek sits down to discuss how healthcare organizations can flatten the curve in the spike of cybersecurity incidents that we are seeing during the COVID-19 pandemic. He will discuss strategies to leverage training materials designed to increase the information security IQ for health care providers and administrative staff working from home or using their personal devices to access information networks. David will also explore why video conferencing and text messaging technologies that meet the requirements of the HIPAA Security Rule standards could provide healthcare organizations resilience in this exceptional time.Podcast Links: View the HHS.Gov Visio-Emergency Preparedness Disclosures chart: https://www.hhs.gov/sites/default/files/ocr/privacy/hipaa/understanding/special/emergency/emergencyprepdisclose.pdf Read a contributing article from David Holtzman: Tips for Secure Remote Worksites, Telehealth Video, and Messaging https://bit.ly/3br5jlz Read a recent article from David Holtzman about how OCR relaxed HIPAA Rules for COVID-19 testing sites: https://bit.ly/3eBZKmp.

Dave shares the details of New York’s new data breach notification law and how it may affect businesses. Ben examines the Electronic Frontier Foundation’s approach to evaluating government demands for new surveillance powers. And later in the show our conversation with David Holtzman from CynergisTek. We’ll be looking at how HIPAA privacy and security standards have been impacted by the federal response to the Covid-19 pandemic. Links to stories: New York’s New Data Breach Notification Law: What Businesses Should Know How EFF Evaluates Government Demands for New Surveillance Powers Listener on the line: First-Ever CCPA Cause of Action Filed in a Federal Court, but Is This Class Claim Short-Lived? Got a question you'd like us to answer on our show? You can send your audio file to caveat@thecyberwire.com or simply leave us a message at (410) 618-3720. Hope to hear from you.  Thanks to our sponsor, KnowBe4.

This podcast features David Holtzman, Executive Advisor for CynergisTek, who discusses how healthcare providers can remain compliant with the HIPAA privacy, security and breach notification rules during the COVID-19 pandemic. Learn how the HIPAA privacy and security standards have been impacted by the federal government's response to the pandemic; the rules for sharing PHI in a public health emergency; which messaging and video conferencing applications are safe to use for telehealth; the status of HIPAA enforcement; and what constitutes “good faith” in treatment and is not subject to penalty. He recommends healthcare organizations visit the OCR website at https://www.hhs.gov/hipaa/ for the latest information. Our podcast host is Janet Kennedy of Get Social Health.

David Holtzman, executive advisor at CynergisTek talks about OCR and its recent notification regarding its enforcement discretion in applying penalties for violations of the HIPAA rules for health care providers using telehealth during the current Coronavirus or COVID-19 health emergency.  If you would like to view the slides while listening to this episode visit https://youtu.be/ngtN7NQoMX4. 

Difficulty sleeping affects many people with Alzheimer's: sleeping longer than usual, trouble falling asleep or staying asleep, or sleeping during the day and being awake at night. For those who do not have Alzheimer's, regularly getting inadequate sleep can increase your risk for the disease.What does research tell us about the link between insomnia and Alzheimer's? And are there steps we can take to help manage the risk created by poor sleep?Host Meryl Comer speaks with two experts on these questions: David Holtzman, MD, of Washington University in St. Louis has led studies linking sleep disorders to greater amyloid-beta and tau accumulation in the brain and thus to an increased risk of developing Alzheimer's.Kristine Yaffe, MD, of the University of California, San Francisco, is an expert on populations studies as well as sleep and Alzheimer’s disease.Support the show (https://www.usagainstalzheimers.org/ways-donate)

David M. Holtzman, MD of the Washington University School of Medicine discusses the mechanisms underlying neurodegeneration and how microglia and specific microglial genes such as TREM2 influence neurodegeneration in the setting of Aβ and tau pathology. Learn how this line of study may lead to new therapeutics and diagnostic testing for Alzheimer's disease. Series: "Brain Channel" [Professional Medical Education] [Show ID: 35262]

David M. Holtzman, MD of the Washington University School of Medicine discusses the mechanisms underlying neurodegeneration and how microglia and specific microglial genes such as TREM2 influence neurodegeneration in the setting of Aβ and tau pathology. Learn how this line of study may lead to new therapeutics and diagnostic testing for Alzheimer's disease. Series: "Brain Channel" [Professional Medical Education] [Show ID: 35262]

David M. Holtzman, MD of the Washington University School of Medicine discusses the mechanisms underlying neurodegeneration and how microglia and specific microglial genes such as TREM2 influence neurodegeneration in the setting of Aβ and tau pathology. Learn how this line of study may lead to new therapeutics and diagnostic testing for Alzheimer's disease. Series: "Brain Channel" [Health and Medicine] [Education] [Professional Medical Education] [Show ID: 35262]

David M. Holtzman, MD of the Washington University School of Medicine discusses the mechanisms underlying neurodegeneration and how microglia and specific microglial genes such as TREM2 influence neurodegeneration in the setting of Aβ and tau pathology. Learn how this line of study may lead to new therapeutics and diagnostic testing for Alzheimer's disease. Series: "Brain Channel" [Health and Medicine] [Education] [Professional Medical Education] [Show ID: 35262]

David M. Holtzman, MD of the Washington University School of Medicine discusses the mechanisms underlying neurodegeneration and how microglia and specific microglial genes such as TREM2 influence neurodegeneration in the setting of Aβ and tau pathology. Learn how this line of study may lead to new therapeutics and diagnostic testing for Alzheimer's disease. Series: "Brain Channel" [Health and Medicine] [Education] [Professional Medical Education] [Show ID: 35262]

David M. Holtzman, MD of the Washington University School of Medicine discusses the mechanisms underlying neurodegeneration and how microglia and specific microglial genes such as TREM2 influence neurodegeneration in the setting of Aβ and tau pathology. Learn how this line of study may lead to new therapeutics and diagnostic testing for Alzheimer's disease. Series: "Brain Channel" [Professional Medical Education] [Show ID: 35262]

David M. Holtzman, MD of the Washington University School of Medicine discusses the mechanisms underlying neurodegeneration and how microglia and specific microglial genes such as TREM2 influence neurodegeneration in the setting of Aβ and tau pathology. Learn how this line of study may lead to new therapeutics and diagnostic testing for Alzheimer's disease. Series: "Brain Channel" [Professional Medical Education] [Show ID: 35262]

David M. Holtzman, MD of the Washington University School of Medicine discusses the mechanisms underlying neurodegeneration and how microglia and specific microglial genes such as TREM2 influence neurodegeneration in the setting of Aβ and tau pathology. Learn how this line of study may lead to new therapeutics and diagnostic testing for Alzheimer's disease. Series: "Brain Channel" [Professional Medical Education] [Show ID: 35262]

David M. Holtzman, MD of the Washington University School of Medicine discusses the mechanisms underlying neurodegeneration and how microglia and specific microglial genes such as TREM2 influence neurodegeneration in the setting of Aβ and tau pathology. Learn how this line of study may lead to new therapeutics and diagnostic testing for Alzheimer's disease. Series: "Brain Channel" [Professional Medical Education] [Show ID: 35262]

David M. Holtzman, MD of the Washington University School of Medicine discusses the mechanisms underlying neurodegeneration and how microglia and specific microglial genes such as TREM2 influence neurodegeneration in the setting of Aβ and tau pathology. Learn how this line of study may lead to new therapeutics and diagnostic testing for Alzheimer's disease. Series: "Brain Channel" [Health and Medicine] [Education] [Professional Medical Education] [Show ID: 35262]

New research has prompted the call for poor sleep to be treated as a public health crisis after it was linked with an increased chance of developing Alzheimer's disease.The researchers are warning that it could lead to a public health crisis and deserves as much attention as the obesity epidemic.Neurology professor at Washington University, David Holtzman told Tim Dower lack of sleep is linked with a number of diseases."This link with different diseases, both outside the brain and inside the brain...is a real issue that tells us we need to be changing our lifestyle.""We know that in diseases like Alzheimer's, proteins accumulate in the brain and what the lack of sleep is doing is, it's causing an increase in one of these proteins to accumulate and spread around the brain."Holtzman said with the increase in average lifespan, Alzheimer's is becoming more of an issue."What you don't want to do is get in a situation where the remainder of your life is not one that one can enjoy, so that's why sleep is so critical."He said deep sleep is really important for staying healthy."We did not look yet look at what are the things that can protect against that, but presumably, getting better deep sleep (slow wave sleep) is one of the ways to decrease the risk of getting this problem."Holtzman said people need to change their lifestyles to make sure they are getting enough sleep."One of the big issues is that people need to try to have a regular schedule of when they go to sleep and wake up, and one of the ways to do that is to stay active during the day, exercise, all of those things prompt having a regular schedule."Technology is also having a negative impact on people's sleep, he said."It's probably not good to have your TV in your room at night when you go to sleep, that's more light and another reason not to stay awake longer.""Make sure the lights in your room where your sleeping are really out and there's no seepage of light.""Try not to be constantly in front of a computer, especially in the time right before you're about to go to bed."Older people need less sleep than younger people.

CynergisTek is a cybersecurity and information management consulting firm dedicated to serving the healthcare industry. In this podcast, David Holtzman,VP of Privacy and Security Compliance Services, discusses cybersecurity threats like ransomware and how CynergisTek can help. Feel free to leave a comment/review!  Visit us at: https://nchica.org/ https://www.facebook.com/NCHICAOrg/ https://www.linkedin.com/company/nchica Twitter @NCHICAorg

David Holtzman of CynergisTek reviews the 2017 HIPAA audit process, lessons learned from the 2016 desk audits, and explains the steps organizations can take to prepare for an audit. You can hear his full presentation on Monday, Sept. 11 at the NCHICA Annual Conference in Durham, NC.

Clark hasn't had any sugar in a week and our guest had an emergency and couldn't make it. so KillDozer (Justin) and Lord Battle (Russell) have to fend for themselves as they discuss “Casting Jonbenet”, “David Holtzman's Diary”, “UFO Abduction”, and “Dead Hands Dig Deep”. If you'd like to get in contact with us, you can reach us at Podcast@TheOverlookTheatre.com or on Instagram, Facebook, or Twitter under @OverlookTheatre.

According to the National Institute on Aging, experts estimate that more than five million people in the United States have Alzheimer's disease, a condition that damages memory and cognitive function. David Holtzman - professor and chair of the neurology department at the Washington University School of Medicine, and associate director of the Charles F. and Joanne Knight Alzheimer's Disease Research Center - explains what is happening in the brain of someone with Alzheimer's. He also describes his own laboratory's research into the disease and shares why he believes that it should be treatable. A version of this podcast was first released in our 2012 series on Memory.

[intro music]   Host – Dan Keller Hello, and welcome to Episode Thirty-Two of Multiple Sclerosis Discovery, the podcast of the MS Discovery Forum. I’m your host, Dan Keller.   This week’s podcast features an interview with Dr. David Holtzman of Washington University in St. Louis about how a protein implicated in Alzheimer’s disease may also have a role in MS progression. But to begin, here's a brief summary of some of the latest developments on the MS Discovery Forum at msdiscovery.org.   We recently added a new data visualization to our growing collection. This one organizes every ongoing MS clinical trial—142 of them—into an interactive bubble chart. The size of each bubble represents the sample size of the trial, and the color indicates if the compound has been used to treat MS before. You can organize the chart 10 different ways, including by phase, compound, and sponsor. Go to the “Research Resources” section of our page and click on “data visualizations” to view it.   Yet another Phase 2 trial on autologous hematopoietic stem cell transplant was published last week. We reported on this trial’s results and how it was different from previous trials we covered. Like the last two studies we reported on, this current study yielded very encouraging results. To view all of the stem cell stories, go to the “news and future directions” section of our website and look for any story with an image of a mouse in a little white lab coat.   New research from the journal Neurology suggests that imaging measurements of the spinal cord and retina independently correlate to disability. Specifically, damage in the two structures was related to visual acuity and to the patient’s ability to discern vibration sensation. The authors suggested that clinicians may want to incorporate scans of the spinal cord and retina into their routine practice.   [transition music]   Now to the interview. Dr. David Holtzman is Chairman of the Department of Neurology at Washington University. He met with MSDF senior science journalist, Carol Cruzan Morton, at a recent Keystone meeting in Taos, New Mexico, to discuss how his work on apolipoprotein Ein Alzheimer's disease may be relevant to MS.   Interviewee – David Holtzman Most of my career has been focused on trying to understand the pathogenesis of Alzheimer's disease, as well as to develop better diagnostic and treatment methods. However, in doing that – in trying to study the science behind that disease – I've also worked a lot on how normal brain function might be related to not only Alzheimer's disease but just some of the proteins that are involved in both Alzheimer's disease and related disorders.   Interviewer – Carol Cruzan Morton We're at the Keystone meeting on neuroinflammation in Taos, New Mexico, and at the talk this morning you mentioned that there might be a connection between the ApoE and this protein involved in Alzheimer's and MS. Can you talk a little bit more about how that protein works normally in an Alzheimer's, and how you came to make that connection to multiple sclerosis?   Dr. Holtzman Sure. Apolipoprotein E first just in terms of a risk factor for Alzheimer's disease ApoE is present as a protein in all of our bodies. It's made in the brain; it's made by the liver; it's at very high levels in the bloodstream. ApoE plays a role in the bloodstream in transporting lipids around the body. It turns out, though, that if the only thing it did was to transport lipids in the blood then you would probably only need to produce it in the liver so that it was secreted into the blood. But interestingly, it's also produced in several other organs: the ovary, the testes, the brain, and a few other places. So in those other organs, it doesn't probably have exactly the same function that it does when it's made by the liver. But the form of the lipoprotein that's in the brain that ApoE is within is somewhat different than it is, for example, in the bloodstream. It's in what's called HDL or high-density lipoproteins in the brain.   MSDF That's a good thing, right?   Dr. Holtzman That's the good cholesterol. That's the good cholesterol in the blood. In the brain, it's not entirely clear what these HDL lipoprotein particles are really doing. So, for example, if ApoE is absent from the brain of a person, and there are people that have genetic mutations, they have no ApoE in their body…   MSDF Completely gone.   Dr. Holtzman Completely gone. And they have developed serious problems with cholesterol buildup in their arteries because they can't clear big lipoprotein particles from their blood, but their brain is okay, no problem. The people are born normal; brain is okay. And there are probably other proteins in the brain that may be able to takeover for its function in the brain; whereas in the blood that's not the case.   MSDF And when it goes wrong in Alzheimer's, what's happening…?   Dr. Holtzman So that's a different issue. So in Alzheimer's disease, there's no lack of ApoE. In humans, there's three different flavors of ApoE: ApoE2, ApoE3, or ApoE4. And there's a very, very subtle difference between the ApoE2, 3, and 4; just really, really small difference. So brain function in people that are of different ApoE types is normal when they're born and when they grow up and as adults. But for some reason – which we'll talk about in a moment – when people have the ApoE4 form of ApoE, it causes a higher risk for Alzheimer's disease probably because it's promoting the buildup of one of the proteins that's really important in causing Alzheimer's disease earlier. So this amyloid protein that builds up in Alzheimer's is strongly influenced by the form of ApoE that you produce. So if you make the E4 form, it's probably because amyloid doesn't get cleared away as well; it builds up earlier. And if you have the ApoE2 form, which is protective against Alzheimer's disease, it pushes out the development of amyloid deposition until very old ages, if ever. That may be something that's related to Alzheimer's disease that's distinct from what it might do in other diseases of the brain like MS, for example.   MSDF How did you make that connection to MS?   Dr. Holtzman Right. So over the years, there's been a number of scientists and physicians around the world who have studied the many possible functions of ApoE in the body. And for gosh it's been about 30 years or so, there's been reports that one of the things that ApoE does is to influence inflammatory cells: T cells, macrophages, etc.   MSDF All over the body or in the brain and spine?   Dr. Holtzman Yeah, in different locations actually. It's never been completely clear exactly what ApoE is doing to the immune system. A lot of studies individually show effects, but it's not entirely clear what it's doing. And so, I got interested in this personally a few years ago there was a prominent paper published suggesting that one of the things that ApoE does to the immune system outside the brain is to help present antigens to the immune system if they contain lipids. And so, that caught my attention because, one, ApoE carries lipids. And just naively I thought well if it helps present lipid antigens in multiple sclerosis the antigens that are being attacked generally are the lipid related antigens.   MSDF The myelin.   Dr. Holtzman The myelin, right, exactly. So I thought well that seems, you know, maybe there's something to this that one could study in relation to MS because of that.   MSDF And then how did you go about asking those question? Where did you start?   Dr. Holtzman Basically, I thought alright, well a lot of people who work on MS if they use animal studies use the model EAE. So we thought well some of my colleagues at Washington University have been using the EAE model for years – like many people have – and so we thought well the obvious experiment to try first is just compare animals that express ApoE in their body versus those that don't. And simply ask the question is there anything different about EAE in an animal that lacks ApoE or not? And so, first, we started working with Anne Cross and then later with Greg Wu together who are experts in using animal models of MS. And ultimately published findings showing – and a few other groups have worked on this, as well – showing that there appears to be decreased clinical severity of EAE in a slightly later onset of disease in animals that lack ApoE.   MSDF And what does that tell you…there might be a role or…?   Dr. Holtzman Obviously many other studies would need to be done to know if it has a role in human MS. But once we found that, particularly Greg's lab began to ask the question well if that's true what's the mechanism? If there is a mechanism that we could hone in on, is that something that seems logical based on what we actually know about ApoE already? And so, the things that kind of came out of our first series of studies was that – unlike what I initially had thought from this earlier paper – it doesn't appear that ApoE is modifying antigen presentation of cells or the ability of T cells to react against the brain. But something once T cells do get in the brain to attack myelin and other components, there's something about that ApoE is acting on at that point. It could be that it's involved in allowing the myelin to repair, or alternatively it could be that when T cells get into the brain and interact with other cells in the brain – like other immune cells like microglial cells or dendritic cells – that that interaction is altered by ApoE within the brain. That might make sense given that ApoE is highly expressed by macrophages outside the brain, and inside the brain it's highly expressed by what are called activated microglial cells. So kind of the macrophages of the brain. So that's where we kind of are now, and I think there's a lot more studies that could be done to really understand both that interaction as well as whether human ApoE causes the same effect that we saw in animals as mouse ApoE. Because they're not exactly the same; they're similar but not the same.   MSDF Is there other evidence connecting ApoE or its various forms with MS?   Dr. Holtzman There are human studies that have been done trying to ask the very simple questions of is the ApoE4, which is a risk factor for Alzheimer's, is that over represented in MS? Or is the ApoE2 form, which is under represented in Alzheimer's, is that protective against MS? And the studies on this some have suggested effects, some haven't. There's no clear answer. But I think if ApoE is involved in MS, it would be less likely to be involved in whether you get MS but more likely involved in the progression of the disease. And I know in the MS field one of the big areas now – now that there's so many studies and as well as treatments that have emerged that are quite effective at suppressing the initial phases of MS, the immune response phases – a lot the work is going into understanding this prolonged progressive phase of MS. And that's where ApoE could be important in sort of the repair and recovery of neurons and axons, for example. Because the fact it transports lipids between cells, maybe it has something to do with recovery of the brain after injury. And that's been speculated on for some time, although not as much work on that has been done in MS.   MSDF Has it been speculated on in MS or MS and Alzheimer's both or…?   Dr. Holtzman No, it's been speculated on after a variety of different brain injuries that it plays a role in redistributing lipids in the brain after injury, and that might be promoting recovery. So one possibility that still hasn't really been tested that I'm aware of in models of MS or in human MS is to whether that really happens for ApoE in the human brain or animal models.   MSDF Can that be tested now?   Dr. Holtzman Absolutely, absolutely. Those are some of the studies that I think are really critical as the next step.   MSDF Is it conceivable that the body of knowledge for Alzheimer's research on ApoE might yield a treatment for progressive MS?   Dr. Holtzman It's possible. I mean a lot of the understanding of what ApoE might be doing in the brain has really expanded because people have been studying Alzheimer's disease and its relationship with ApoE. So I can't imagine it wouldn't help with that because we've learned a lot so far.   MSDF Are there other treatments in the pipeline for Alzheimer's related to ApoE?   Dr. Holtzman There are. There's not too many things yet that have reached human trials, but there are groups trying to alter the level of ApoE in the brain or to alter its receptors in the brain as potential treatments for affecting Alzheimer's disease. So yeah, I mean those are the kind of things, as they advance, depending on what's found in regard to the relationship between ApoE and MS could be tried in MS. I don't see why not.   MSDF That's interesting. What else should I be asking?   Dr. Holtzman I think what scientifically what I think is really important to still sort out in this area is that when the innate immune cells of the brain – the microglial cells or even macrophages when they get into the brain – they produce tremendous levels of ApoE when that happens. And I think understanding what that protein is really doing in that setting could provide insight into future treatments. So that's what I think is really fascinating to try to understand.   MSDF Well if it happens in Alzheimer's, as well, it happens before the blood-brain barrier breaks down and then after it, it sounds like.   Dr. Holtzman Well, in MS, it's probably occurring after there's cell entry into the brain. But the upregulation of ApoE by these innate immune cells is much higher in MS than it is in Alzheimer's disease.   MSDF Oh, is that right?   Dr. Holtzman Yeah, yeah.   MSDF That's interesting. That's even more interesting.   Dr. Holtzman Yeah, I know. That's why it's really, really fascinating. I think one of the figures from the paper that we published last year from Greg's lab showed that the level of ApoE increasing in microglial cells versus similar cells that are present in the spleen of an animal is like 25 times higher in the setting of an EAE model than normal. So it's really, really high. Is it really doing anything, or is it just a byproduct? I suspect it probably is doing something. So that's what I think would be really interesting to figure out.   MSDF Thanks. Well I appreciate your taking time out at the Keystone meeting to talk with MS Discovery Forum.   Dr. Holtzman Yeah, it's great. Well good luck. MS is such a…the treatments that have been evolving are so exciting compared to Alzheimer's disease where we don't yet have good treatments. So I think there will be soon, but I think it's a great opportunity to even advance for ...   MSDF Is there a chance that the reverse could be true? That treatments existing for MS would be helpful in Alzheimer's?   Dr. Holtzman That's a good question. I don't know if any of the frequently used ones where you're preventing cell entry into the brain necessarily would be useful for Alzheimer's. But like one of the new drugs, Tecfidera, this oral medication does do some interesting things to cells in the brain that might be useful in a disease like Alzheimer's. So maybe there will be some things that we can translate.   MSDF I appreciate it. Thank you so much.   Dr. Holtzman Thank you.   [transition music]   Thank you for listening to Episode Thirty-Two of Multiple Sclerosis Discovery. This podcast was produced by the MS Discovery Forum, MSDF, the premier source of independent news and information on MS research. MSDF’s executive editor is Robert Finn. Msdiscovery.org is part of the non-profit Accelerated Cure Project for Multiple Sclerosis. Robert McBurney is our President and CEO, and Hollie Schmidt is vice president of scientific operations.   Msdiscovery.org aims to focus attention on what is known and not yet known about the causes of MS and related conditions, their pathological mechanisms, and potential ways to intervene. By communicating this information in a way that builds bridges among different disciplines, we hope to open new routes toward significant clinical advances.   We’re interested in your opinions. Please join the discussion on one of our online forums or send comments, criticisms, and suggestions to editor@msdiscovery.org.   [outro music]          

Dr. David Holtzman is the Andrew B. and Gretchen P. Jones Professor and Chairman of Neurology, Professor of Developmental Biology, Associate Director of the Alzheimer's Disease Research Center, and a Head of the Hope Center for Neurological Disorders. David received his Medical Degree from Northwestern University and completed Residency in Neurology at the University of California, San Francisco. David has received many awards and honors during his career, including a Paul Beeson Physician Faculty Scholar Award in Aging Research, the Potamkin Prize from the American Academy of Neurology for research on Alzheimer's disease, a MERIT award from the National Institute on Aging, the MetLife Award for research on Alzheimer's disease, and two of his research discoveries were listed in the top 50 scientific innovations in 2006 by Scientific American. He is also an elected member of the American Neurological Association, the American Society for Clinical Investigation, and the Institute of Medicine of the National Academy of Sciences. David is here with us today to tell us all about his journey through life and science.

1) Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease and 2) Topic of the month: Plenary sessions AAN Meeting April 2014. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Mytinger interviews Dr. Russell Dale about his paper on utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Dr. James Addington is reading our e-Pearl of the week about pseudo-internuclear ophthalmoplegia. In the next part of the podcast Dr. Alberto Espay interviews Dr. David Holtzman about his Robert Wartenberg Lecture at the AAN Meeting about Alzheimer's disease in 2014: Mapping a road forward. The participants had nothing to disclose except Drs. Dale, Addington, Espay and Holtzman.Dr. Dale serves on the scientific advisory board for Queensland Children's Medical Institute; serves as an editorial advisory board member of Multiple Sclerosis and Related Disorders Journal; received honoraria for lecturing from Biogen Idec; receives research support from the National Health and Medical Research Council. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of Novartis, UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Holtzman serves as an Associate Editor of Annuals of Neurology; serves as an editorial board member of Neurobiology of Disease, Experimental Neurology, Molecular Neurodegeneration, Science Translational Medicine and Journal of Experimental Medicine; co-founder of C2N Diagnostic LLC; is a consultant for AstraZeneca, Genentech, Inc., Bristol-Myers Squibb and Forum Pharmaceuticals; receives research support AstraZeneca, Eli Lilly and Company, Biogen Idec, C2N Diagnostic LLC, Cure Alzheimer's Disease, Tau Consortium, Ellison Medical Foundation and the NIH.

How blocking tau protein tangles in the brain may combat neurodegeneration, with David Holtzman (0:00) (from Neuron). How the US government is betting big on neuroscience research, with Cori Bargmann (6:42) (from Cell). How a common virus is linked to several kinds of cancers, with Henri-Jacques Delecluse (16:50) (from Cell Reports). Plus, sample a selection of the hottest new papers from Cell Press (21:20).

Autism and Mitochondrial Disease, Feb 6 2009 with guest Dr. David Holtzman

David Holtzman is a former security analyst and military code-breaker, a futurist, activist, technologist, technology executive, and writer. Throughout his career, he has led initiatives that have radically changed the way people interact with technology. Holtzman is an Internet pioneer who helped oversee the Internet's growth from its infancy in the mid-1990s through the dot-com boom. As Chief Technology Officer of Network Solutions and the manager of the Internet's master root server, he ran the most critical network in the world - the domain name system - and oversaw the growth of the commercial Internet from 500,000 to over 20 million domain names